Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Leigh Ellis

Uniformed Services University of the Health Sciences

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines1

Latest

Everything in the corpus, newest first.

AUG 14, 2026 · JOURNAL ARTICLE

EZH2 Inhibition and Myeloid Risk: A Feature of On-Target Biology

Clinical Cancer Research

A regulator-initiated market withdrawal based on confirmatory Phase Ib/III trial data showing a clinically significant safety signal (hematologic SPMs) that changes the risk–benefit profile of an approved agent.

Regulatory UpdateProstate Cancer Treatment and Research Leigh Ellis Epigenetics and DNA Methylation

Reported

Incidence of hematologic SPMs in…5.7%

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support